Oral supplementation almost never produces symptoms because the body absorbs only a small fraction of high-dose oral B12 and excretes the rest
These include: Nausea, vomiting, and diarrhoea (very common, especially during dose escalation) Reduced appetite and abdominal discomfort Constipation Risk of hypoglycaemia when used with insulin or sulphonylureas Pancreatitis and gallbladder disease have been reported Thyroid C-cell tumours have been observed in animal studies, though the relevance to humans is unknown Important safety considerations when using both treatments include: Mounjaro can reduce the effectiveness of oral contraceptives due to delayed gastric emptying
The effect was due to on-target inhibition of GPX4 rather than reduction of GSH levels, as, contrary to the marked reduction in GSH observed with L-buthionine-sulfoximine (BSO), we observed only a small reduction with SCLA2 at 10 M and no change at 1 M (Extended Data Fig
Biological product research and development, medical technology research and development
Im Vergleich zu Retinol verursachen sie meist seltener Trockenheit, Schuppung oder Reizungen
